# AS703569 and Gemcitabine Combination in Advanced Malignancies

> **NCT01097512** · PHASE1 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 66 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** AS703569/gemcitabine
- **DRUG:** AS703569/gemcitabine

## Key facts

- **NCT ID:** NCT01097512
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2010-07
- **Final completion:** 2011-02
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2014-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01097512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01097512, "AS703569 and Gemcitabine Combination in Advanced Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01097512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*